Receptor activator of nuclear factor κB expression is a prognostic factor in human osteosarcoma

Oncology Letters

Volumn 10, Issue 3, 2015, Pages 1813-1815

  Trieb, Klemens ^a,b   Windhager, Reinhard ^c  

^a Klinikum Wels Grieskirchen   (Austria)

^b Klinikum Frankfurt Oder GmbH   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Expression; Osteosarcoma; Prognosis; Receptor activator of nuclear factor B

Indexed keywords

RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CELL VIABILITY; CHILD; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PREOPERATIVE CARE; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 84937459463     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3489     Document Type: Article

References (18)

1. DavisAM, BellRS and GoodwinPJ: Prognostic factors in osteosarcoma: A critical review. J Clin Oncol12: 423-431, 1994.
2. BielackSS, Kempf-BielackB, DellingG, ExnerGU, FlegeS, HelmkeK, KotzR, Salzer-KuntschikM, WernerM, WinkelmannW, etal: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol20: 776-790, 2002.
3. TriebK and KotzR: Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol33: 11-17, 2001.
4. MogiM and KondoA: The presence of RANKL-OPG complex in human osteosarcoma U2OS. J Immunoassay Immunochem34: 356-364, 2013.
5. BeristiainAG, NaralaSR, DiGrappaMA and KhokhaR: Homotypic RANK signalling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells. J Cell Sci125: 943-955, 2012.
6. RousseauJ, EscriouV, LamoureuxF, BrionR, ChesneauJ, BattagliaS, AmiaudJ, SchermanD, HeymannD, RédiniF and TrichetV: Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. J Bone Miner Res26: 2452-2462, 2011.
7. Lee JA, Jung JS, Kim DH, Lim JS, Kim MS, Kong CB, Song WS, Cho WH, Jeon DG, Lee SY and Koh JS: RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr Blood Cancer56: 738-743, 2011.
8. AkiyamaT, DassCR, ShinodaY, KawanoH, TanakaS and ChoongPF: Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts. J Pharm Pharmacol62: 470-476, 2010.
9. MoriK, AndoK, HeymannD and RédiniF: Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells? Histol Histopathol24: 235-242, 2009.
10. MoriK, BerreurM, BlanchardF, ChevalierC, Guisle-MarsollierI, MassonM, RédiniF and HeymannD: Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep18: 1365-1371, 2007.
11. Bago-HorvathZ, SchmidK, RösslerF, Nagy-BojarszkyK, FunovicsP and SulzbacherI: Impact of RANK signalling on survival and chemotherapy response in osteosarcoma. Pathology46: 411-415, 2014.
12. Ennking WF, Spanier SS and Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res153: 106-120, 1980.
13. Salzer-KuntschikM, BrandG and DellingG: Determination of the degree of morphological regression following chemotherapy in malignant bone tumors. Pathologie4: 135-141, 1983 (In German).
14. TriebK, SulzbacherI and KubistaB: Bcl-2 correlates with localization but not outcome in human osteosarcoma. Oncol Lett6: 559-561, 2013.
15. ZhuY, ZhouJ, JiY and YuB: Elevated expression of AKT2 correlates with disease severity and poor prognosis in human osteosarcoma. Mol Med Rep10: 737-742, 2014.
16. WangX, DuJ, GuP, JinR and LinX: Polymeric immunoglobulin receptor expression is correlated with poor prognosis in patients with osteosarcoma. Mol Med Rep9: 2105-2110, 2014.
17. XuSH, YangYL, HanSM and WuZH: MicroRNA-9 expression is a prognostic biomarker in patients with osteosarcoma. World J Surg Oncol12: 195, 2014.
18. TriebK, LechleitnerT, LangS, WindhagerR, KotzR and DirnhoferS: Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy. Hum Pathol29: 1050-1055, 1998.